Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QTP101 in older adults for TB prevention
NCT06714513Phase 1Recruiting
- Sponsor
- Quratis
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ID93 + GLA-SE in Tuberculosis (TB) (12 arms), sponsored by Quratis. Primary endpoints: Immediate Adverse Events, Solicited Local and Systemic Adverse Events and 7 more. Started May 2025; status: recruiting.
02
Drugs
ID93 + GLA-SE
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06714513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714513.